Melanoma cells facilitate endothelial gap formation, the first step during tumor transendothelial migration, which is mediated by both adhesion and endogenously produced chemokines (in particular, interleukin-8 (IL-8)). Tetraspanins are localized to the cell surface in cancer and participate in various functions including invasion of tissues mediated by secretion of cytokines and matrix metalloproteinases. However, little is known about the role of CD82 tetraspanins in malignant melanomas during cancer cell invasion. In this study, we investigated the functional importance of CD82 expression in melanoma-mediated gap formation by using cDNAs to induce CD82 expression in highly invasive melanoma cell lines. Results showed that CD82 expression inhibited melanoma cell-induced gap formation, melanoma cell extravasation in vitro and subsequent lung metastasis development in vivo. Mechanistic studies showed that inducible expression of CD82 in highly metastatic melanoma cells significantly increased p21 expression upon binding of Duffy antigen receptor group (DARC), inducing tumor cell senescence and interrupting IL-8-mediated vascular endothelial (VE)-cadherin disassembly. Taken together, these studies provide a rationale for using drug therapies that restore CD82 expression and inhibit IL-8 production to inhibit late-stage melanoma cell extravasation and subsequent metastasis development.
INTRODUCTION
Metastasis is a complex process requiring melanoma cell detachment from its primary location and migration through blood or circulatory systems to secondary sites. Once cancer cells metastasize to reach distant organs, cancers become increasingly difficult to treat using current therapies warranting the need to elucidate molecular mechanism during this process. [1] [2] [3] One important event during cancer metastasis is melanoma cell extravasation through the endothelial vessels, which requires 4, 5 (i) the breakdown of vascular endothelial (VE)-cadherins to form gaps, (ii) penetration of the endothelial barrier and (iii) migration of tumor cells through blood vessels into tissues to form metastatic lesions. These events are mediated by adhesion molecules, inflammatory cytokines and proteases that degrade the underlying extracellular matrix. [5] [6] [7] Tetraspanins are a family of membrane proteins present in all tissue types that have a vital role in a wide spectrum of biological functions. 8, 9 In cancers, tetraspanins (including CD82) have a vital role in cellular invasion, particularly during cell movement. [10] [11] [12] Studies have found that expression levels of CD82 tetraspanins decrease in highly metastatic cancers, increasing tumor cell extravasation. 13, 14 While the metastatic-suppressive effects of CD82 have been demonstrated in cell, animal and patient models, 12, 13, 15 the complex molecular mechanism by which CD82 expression suppresses tumor cell extravasation remains unclear.
Previous work has shown that CD82 binds to Duffy antigen receptor/chemokine group (DARC), and furthermore, that DARC expression in endothelial cells is necessary for CD82-mediated tumor suppression. 16, 17 Binding of CD82 on tumor cells to DARC receptors on endothelial cells prevents invasion of CD82-positive tumor cells by inducing senescence in CD82 þ cells. DARC also binds C-X-C and C-C cytokine receptors (including interleukin (IL)-8) secreted by highly metastatic melanoma cells. 16, 18 IL-8 has been shown to be an important factor in mediating tumor cell extravasation through endothelial cells and underlying extracellular matrix. 19, 20 IL-8 binds with high affinity to CXCR2 and DARC rather than CXCR1. 21, 22 Studies in fibroblasts have shown that knocking down DARC diminishes cell senescence and increases tumor cell extravasation. 18, 23, 24 In normal physiology, DARC on endothelial cells modulates IL-8 signaling by acting as a 'chemokine sink' where DARC binds to chemokines, but does not activate downstream signaling pathways. 25 During tumor-induced inflammation, excess secretion of IL-8 within the tumor microenvironment disrupts this homeostasis. In melanoma cells, these effects are exacerbated by synergistic secretion of IL-8 from endothelial cells bound to melanoma cells, facilitating migration of melanoma cells through the blood vessels. [26] [27] [28] [29] [30] [31] Upon IL-8 binding to CXCR2 receptors, signaling pathways such as phosphatidylinositol-3 kinase and/or p38 mitogen-activated protein kinase are activated. This signaling cascade inhibits tumor cell senescence and trigger internalization of VE-cadherin junctions in the endothelial cells forming gaps on endothelial monolayers. [32] [33] [34] [35] [36] [37] [38] Although several studies have focused on CD82 and DARC interactions, the role of CD82 in regulating IL-8 signaling remains unclear.
In melanoma cells, IL-8 binding to endothelial cells have an important role in regulating VE-cadherin disassembly via activation of CXCR2 receptors. 37 However, previous literature shows that ectopic expression of CXCR2 in tumor cells results in tumor cell senescence. 18 These studies show that during oncogene-induced senescence there is an increase in IL-8 that binds CXCR2 receptors on tumor cells to reinforce tumor cell growth arrest and migration. 18 In cancer cells, cell senescence can be reversed by knocking down CXCR2 expression. 16, 39 Although several studies have found that CD82 binding DARC induces tumor cell senescence via a p21-dependent mechanism, [40] [41] [42] [43] [44] [45] [46] [47] the effects of CD82 on IL-8 have not been elucidated.
In this work, we showed that ectopic CD82 expression suppresses IL-8 secretion and that binding of CD82 tetraspanins to DARC receptors interrupts IL-8 signaling in endothelial cells. The p21/Waf1 protein is a cyclin-dependent kinase inhibitor, which binds active cyclin-dependent kinase 2 or cyclin-dependent kinase 4 complexes. 43, 44 Inhibition of cyclin-dependent kinase complexes prevents progression of cells through the G 1 phase of the cell cycle, resulting in growth arrest of cells or cellular senescence. Consistent with previous work, melanoma cells expressing physiological levels of CD82 bound DARC while inducing p21/Waf1 expression in melanoma cells. We extended previous findings to show that CD82 expression in highly invasive melanomas binds available DARC receptors on endothelial cells, interrupting IL-8 binding to the endothelial cell surface and subsequent intracellular signaling within endothelial cells. Furthermore, these binding events induce p21-induced cell senescence preventing melanoma cells with mutant BRAF 48 to migrate through blood vessels, in vivo. These results show that CD82 expression suppresses tumor effects not only via DARC binding, but via regulation of IL-8 secretion, making CD82 an effective therapeutic target for late-stage cancer metastasis.
RESULTS
Restoring CD82 expression in highly metastatic melanoma cells reduces invasion into lung tissues CD82 expression was detected in eight patient samples using western blot analysis. The majority of patients showed low levels of CD82 comparable to invasive melanomas such as A375M and UACC 903M cells (Figure 1a) . To test the hypothesis that CD82 mediates melanoma cell invasion and formation of metastatic lesions, green fluorescent protein (GFP)-tagged UACC 903M or A375M cells were injected via the tail vein into nude mice. Six mice from the control or experimental group were killed 2 weeks later. Compared to vector-transfected cells (3.1 vector), in vivo results showed that CD82-expressing tumor cells significantly decreased the appearance of metastatic lesions in the lungs of nude mice (Figures 1b-d) . High CD82 expression in nucleofected A375M and UACC 903M melanoma cells injected in mice was confirmed using western blots (Figures 1b and c, right panels) . These levels were comparable to endogenous CD82 expression in primary non-invasive melanoma cell lines (WM35 and WM793 melanoma cells) (Figures 1b and c) . In blots 1a, 1b and 1c, total levels of ERK1, ERK2 or a-enolase was analyzed to ensure equal loading of proteins.
In vitro flow chamber experiments showed that inducible CD82 expression in A375M and UACC 903M melanoma cells decreased extravasation under low shear flow compared with the control cases ( Figure 1e , left panels), suggesting that CD82 expression decreased tumor cell extravasation. CD82 expression in cells used for in vitro flow chamber experiments was confirmed using western blot analysis (Figure 1e, right panels) . As CD82 À cells migrate under low shear stresses (0.625 dyn/cm 2 ) rather than high shear stresses (2 dyn/cm 2 ), these results show that CD82 mediates the motility and subsequent extravasation of tumor cells rather than adhesion of tumor cells. However, the role of CD82 in tumor cell extravasation remains unknown.
CD82 expression in highly metastatic lines dramatically reduces in vitro gap formation. As VE-cadherin junctions serve as the primary mediators of endothelial permeability, 37, 41 we hypothesized that CD82 regulates these endothelial junctions. Human umbilical vein endothelial cells (HUVECs) were grown to 98-99% confluency on coverslips and cocultured with A375M melanoma cells transfected with 3.1 vector or CD82 cDNAs. Quantification of the total gap area shows a significant reduction in the total gap area and gap sizes in cells transfected with CD82 (Figure 2a , left) compared with the control cases (3.1 vector), where total gap area and sizes of the gaps are much larger. These results lead to the conclusion that high levels of CD82 expression prevented gap formation. Conversely, knocking down CD82 expression using small interfering RNA (siRNA) increases gap formation (Figure 2a, right) . Gap formation is one important step during tumor cell extravasation. 37 We found that reintroducing CD82 expression in highly invasive melanoma cells decreased tumor cell extravasation through HUVEC monolayers after 4 h ( Figure 2b , top and bottom left panels). CD82 expression in cells was analyzed using western blot analysis ( Figure 2b , top and bottom right panels). These results show that CD82 is an important mediator of VE-cadherin-mediated gap formation.
CD82 expression in highly metastatic lines dramatically reduces gap formation in vitro and invasion of blood vessels To assess whether CD82 affected tumor cell invasion through blood vessels, 1 Â 10 6 GFP-A375M melanoma cells were nucleofected with either empty vector (3.1 vector) or CD82 cDNAs and injected into the lumen of human blood vessels, which were then placed in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) for 3 days. Harvested vessels were fixed and stained for VE-cadherin (red regions). Figure 3a To support our hypothesis that CD82 mediates tumor cell extravasation, a Boyden chamber was used to measure tumor cell extravasation when knocking down IL-8 or CD82 expression. We showed that A375M melanoma cells nucleofected with CD82 or IL-8 siRNA decreased melanoma cell extravasation by 60% ( Figure 4e ). Previous studies have shown that CD82 binds DARC receptors on endothelial cells to induce tumor cell senescence via p21/Waf-1 expression. 16 As CD82 expression regulates IL-8 secretion, we hypothesized that CD82 binding of DARC receptors prevented endothelial response to IL-8 and induced cell senescence via an increase in p21 expression. Figure 5c ). However, in the case of CD82 expressing A375M and UACC 903M melanoma cells, the binding of DARC to CD82 activates p21/ Waf 1 expression, which has been shown to induce melanoma cell senescence and prevent tumor cell extravasation through endothelial monolayers (Figure 5c ). These findings suggest that the direct binding of CD82 and DARC receptors interrupt binding of IL-8 to DARC receptors on HUVECs, preventing invasion through endothelial cells.
DISCUSSION
The progression of melanoma cells from an early benign to malignant state is associated with an increase in cytokine secretion and diminishing CD82 expression. While studies have found that potent inflammatory cytokines influence melanoma development, [49] [50] [51] the exact mechanisms by which inflammatory cytokines are regulated are not well understood. Furthermore, the role CD82 and other tetraspanins have in mediating chemokines remains unknown. In particular, no studies have shown how CD82 regulates IL-8 expression and secretion during tumor/endothelial interactions to promote tumor migration and metastasis development. As outlined in Table 1 , this is the first study to show that CD82 regulates IL-8 secretion and subsequent VE-cadherin disassembly to promote melanoma cell extravasation, and development of metastasis.
This study shows that invasive melanoma cells secrete high levels of IL-8, promoting metastasis melanomas, 52 which can be modulated by CD82. Expression of CD82 in melanoma cells interrupted IL-8-mediated activation of endothelial cells, triggering tumor cell senescence. Thus, reagents promoting the expression of intracellular CD82 in melanoma cells reduced secretion of IL-8 and subsequent melanoma cell invasion, suggesting that therapies that restore CD82 expression could disrupt the metastatic process.
The extravasation of melanoma cells was significantly reduced under low shear flow conditions following expression of CD82 in melanoma cells. These results were confirmed using animal studies where CD82 expression diminished metastatic lesions in vivo, reducing the number of lesions by nearly 95%. Under low shear stresses (0.625 dyn/cm 2 ), late-stage melanoma cells could Restoration of CD82 expression prevents secretion of interleukin-8, a chemoattractant involved in directing melanoma migration and movement
Inhibition of IL-8-mediated endothelial gap formation by CD82/KAI P Khanna et al not extravasate through endothelial monolayers, suggesting that CD82 tetraspanins mediate the motility of melanoma cells during tumor/endothelial interactions. Previous studies have shown that VE-cadherin disassembly and subsequent gap formation is an important event during tumor cell extravasation. 38, 53 This is the first study to show that p21 expression in melanoma cells increases after CD82-expressing melanoma cells bind to DARC receptors, indicating a potential mechanism for reduced extravasation under low shear stresses. This observation is supported by previous studies showing that extravasation is interrupted by p21-induced cell senescence under static conditions. 41 Consistent with previous studies, we found that knocking down CD82 dramatically increased gap formation and subsequent tumor extravasation. Previous studies have reported that an increase in tumor cell extravasation is primarily due to disruption of binding between DARC and CD82 that prevents tumor cell senescence. 37, 45 While DARC has been described as a 'chemokine sink' in erythrocytes, in endothelial cells DARC binds to chemokines and translocates these chemokines to the surface of endothelial cells. 25 In mice with DARC deficiency, vascular permeability dramatically decreased, but these effects were diminished upon the activation of CXCR2 receptors. 25 These studies suggest that inducible DARC expression may not be sufficient to modulate excess chemokines secretion into the tumor microenvironment. Thus, CD82 could provide a therapeutic target that would potentially decrease metastasis development by reducing IL-8 secretion from melanoma cells. New technologies with the potential to target and reduce IL-8 levels in melanoma cells have also been developed to carry siRNAs 54 or an antibodybased immunotherapy specifically targeting secreted IL-8. 29 The obstacles for siRNA-containing liposomes for IL-8 or CD82 siRNAs would be efficiencies high enough for each cell to undergo endocytosis and uptake the siRNA to dramatically decrease secreted IL-8. Similar issues arise in late-stage cancers where targeting tumor cells and inducing DARC expression has been suggested to reduce cancer metastasis. 16, 23 In targeting CD82 using siRNAs would reduce adverse side effects since CD82 is expressed in normal cells.
In conclusion, we have shown that targeting CD82 reduces melanoma metastasis, which is mediated through a reduction of melanoma cell extravasation through the endothelium. Mechanistically, the reduction in melanoma cell extravasation following expression of CD82 is due to the binding of CD82 to DARC receptors. These events disrupt IL-8 binding to endothelial cells and induce p21 expression in tumor cells. Therefore, our study Inhibition of IL-8-mediated endothelial gap formation by CD82/KAI P Khanna et al suggests that targeting CD82 signaling may offer a potential mechanism for therapeutic inhibition of IL-8 function in melanoma cancer.
MATERIALS AND METHODS

Cell lines and culture conditions
HUVECs were purchased from the American Type Culture Collection (Manassas, VA, USA) and were maintained in F12-K medium with 10% FBS, 30 mg/ml of endothelial cell growth supplement, 50 mg/ml heparin (Mallinckrodt Baker Inc., Phillipsburg, NJ, USA) and 100 U/ml of penicillin-streptomycin (Biofluids Inc., Rockville, MD, USA Transfection of cDNAs and selection of stable clones
Five micrograms of pcDNA3.1 hemagglutinin-tagged CD82 or pcDNA3.1 vector control constructs were nucleofected into A375M and UACC 903M melanoma cells. Transfection efficiencies were assessed using pMaxGFP plasmid (Amaxa Biosystems, Koeln, Germany) as a GFP expression plasmid control. Following nucleofection, the cells were plated in 100 mm dish and grown to 60-70% confluency before selecting antibiotic-resistant clones. Puromycin-resistant cells overexpressing CD82 were isolated and CD82 expression levels were confirmed using western blotting. Constitutively active CD82 levels in nucleofected A375M and UACC 903M melanoma cells were compared with endogenous CD82 expression in primary melanoma cell lines (WM35, WM793). SiRNA (100 pmol) was introduced into 1.0 Â 10 6 A375M melanoma cells via nucleofection using an Amaxa Nucleofector using Solution R/program K-17. 52 Transfection efficiency was 495% with 80-90% cell viability. 52 Following siRNA introduction, cells were allowed to recover for 2 days in culture dishes before passaging cells into 96-well plates. After 5 days, cell viability was measured using an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay (Promega, Madison, WI, USA). 52 Duplexed Stealth siRNA (Invitrogen) were used for these studies. The following siRNA sequences were used: scrambled, 5 0 -AAUUCUCCGAACGUGUCACGUGAGA-3 0 ; IL-8 no. 1, 5 0 -GCAG CUCUGUGUGAAGGUGCAGUUU-3 0 ; IL-8 no. 2, 5 0 -CCAAGGAGUGCUAAAGAA CUUAGAU-3 0 ; and CD82, 5 0 -UCUCGAAUGAGCUCAGUCACGAUGC-3 0 .
Surrogate assays
Patient studies. Patient samples were obtained following protocols approved by the Pennsylvania State University Institutional Review Board (IRB). Patients were in the late stage of melanoma and samples from both male and female patients were analyzed for CD82 expression as summarized in Table 2 .
Animal studies. Animal experimentation was performed according to protocols approved by the Institutional Animal Care at the Pennsylvania State University as previously described elsewhere. 55 Tumor formation was measured in athymic female nude mice purchased from Herlan Sprague-Dawley (Indianapolis, IN, USA) . Briefly, 1.0 Â 10 6 A375M or UACC 903M melanoma cells nucleofected with empty vector (3.1 vector) or CD82 were collected in 0.2 ml of Hank's balanced salt solution and then injected intravenously in 4-to 6-week-old female mice. Mice were killed 17 days after cell injection and the presence of fluorescent metastatic lesions was detected using a Nikon SMZ 1500 dissecting microscope. Fifteen images of random fields were photographed at a magnification of Â 40 from each lung and the number of fluorescent lesions counted. Each control or experimental group consisted of six mice.
In vitro flow migration assay. Tumor cell migration was measured using a modified 48-well chemotactic Boyden chamber consisting of a top and bottom plate separated by a gasket. 24 Before each experiment, a monolayer of HUVECs were grown on sterile polyvinylpyrrolidone-free polycarbonate filters (8 mm pore size; NeuroProbe, Gaithersburg, MD, USA) precoated with 2% gelatin diluted in PBS, for 2 h (Sigma-Aldrich, St Louis, MO, USA). The center 12 wells of bottom plate were filled with soluble chemoattractant type IV collagen (100 mg/ml diluted in RPMI 1640 with 0.1% bovine serum albumin; BD Biosciences, San Jose, CA, USA) and surrounding control wells were filled with RPMI 1640 containing 0.1% bovine serum albumin. Previous work has shown that melanoma cells migrate toward collagen IV acting as a chemoattractant. 28 The apparatus was assembled by laying the filter on the bottom plate, followed by a gasket and top plate. The chamber was primed with RPMI 1640 and 0.1% bovine serum albumin to eliminate bubbles from the system. For the migration assay, 2 Â 10 6 GFP-labeled melanoma cells were placed in the chamber and subjected to a shear flow of 0.625 dyn/cm 2 for 4 h in a 37 1C incubator. The total number of cells that migrated after 4 h was counted by imaging 12 fields using an inverted NIKON microscope (NIKON Corporation, Tokyo, Japan). Analysis was carried out using images captured with NIS elements software (NIKON Corporation).
In vivo imaging of human vessels. All patients were given informed consent. All experiments using human material were undertaken according to protocols approved by the Institutional Review Board Committee at The Pennsylvania State University. All procedures were performed according to protocols approved by the Penn State Human Subjects Protection Office. Human veins from human subjects were isolated from discarded patient surgery material remaining from routine surgical procedures and divided into 10-mm sections. Approximately 2 cm of human vessels were clamped at both ends before using 27-G needles, which were used to inject 1.0 Â 10 6 A375M cells with stable pcDNA3.1 or CD82 expression. Human vessels containing GFP melanoma cells were maintained in DMEM (Invitrogen) supplemented with 10% FBS (Thermo Scientific Hyclone, Logan, UT, USA) and penicillin/streptomycin (Invitrogen) for 11 days. Each section was stained using anti-human VE-cadherin antibodies (dilution 10:1000 in PBS/calf serum (CS)/goat serum (GS) solution containing PBS, 2% GS, 5% CS and 0.3 Triton-X). Sections were incubated in antibody overnight at 4 1C and then washed two times with PBS. Sections were incubated using secondary 594 Alexa Fluor goat antimouse antibodies (dilution 1:1000 in PBS/CS/GS) for 1 h at room temperature before washing each section two times with PBS. Each 1-mm section of the vessels was captured ranging from the glass surface of the slide towards the lumen of the vessel using an Olympus Fluoview 1000 confocal microscope (Olympus, Center Valley, PA, USA) with a PlanApo 60X/1.4 oil immersion lens and then reconstructed using 3-D Autoquant deconvolution software (Media Cybernetics, Rockville, MD, USA). The number of melanoma cells in each section of the reconstructed vessel was quantified and plotted using Sigma Plot software (Systat Software Inc, San Jose, CA, USA).
Fluorescence imaging and analysis
Before starting the experiments, 25-mm coverslips were washed with PBS and then equal concentrations of HUVECs were then grown to 95-99% confluency. HUVECs were cocultured with melanoma cells for 45 min. Cells were then fixed with 5% formaldehyde in PBS for 10 min. Cells were permeabilized with PBS/CS/GS solution for 20 min. Coverslips were incubated for 1 h in primary VE-cadherin antibodies (10:1000 dilution in PBS/CS/GS solution) and washed two times with PBS. Finally, each of the coverslips was incubated with Alexa Fluor 488/520 goat anti-mouse immunoglobulin G (IgG) antibody (dilution of 1:1000). The coverslips were incubated at room temperature for 1 h and rinsed with PBS three times before imaging using a NIKON TE-2000 microscope. For each experimental condition, one coverslip was viewed under a Â 40 objective and a series of six images were taken of randomized fields using an EZ coolsnap camera. Each image was then analyzed using the Image J software version 1.32 (National Institutes of Health, Bethesda, MD, USA). 37 Analysis of gaps and disruption of VE-cadherin Disruption of VE-cadherin was identified by areas lacking green fluorescence at VE-cadherin junctions between HUVECs. Gap area within disrupted VE-cadherin junctions was determined from six images (see arrows in Figure 2b in the Results section as an example). Gap area was quantified as the ratio of pixels within all the gaps and the total number of pixels in one image. 37 The average percent of endothelial gaps was calculated from six images and plotted as a function of time.
Immunoprecipitation and western blots. For co-immunoprecipitation of CD82 and DARC, we mixed the CD82 þ tumor cells (A375M or UACC melanoma cells) with HUVECs in the presence of the cell-impermeable crosslinker DTSSP (3, 3 0 -dithiobis(sulfosuccinimidylpropionate)) for 30 min at 24 1C. Whole-cell extracts were prepared by resuspending cells in 2 ml of lysis buffer (1% NP-40, 10 mM Tris, pH 8.0, 150 mM NaCl, 3 mM MgCl 2 and 2 mM phenylmethanesulfonylfluoride). Lysates were incubated on ice for 30 min, followed by centrifugation at 16 000 g for 5 min at 4 1C. The pellet was discarded and the supernatant was immunoprecipitated with antibody to DARC in the presence of protein G agarose beads. After immunoprecipitation, we analyzed bound proteins by western blot using CD82 (1:1000) and IL-8 (1:1000) antibodies. The lysate was mixed with 2 Â sodium dodecyl sulfate running buffer (0.2% bromophenol blue, 4% sodium dodecyl sulfate, 100 mM Tris, 200 mM dithiothreitol, 20% glycerol) in a 1:1 ratio. Forty microliters was loaded onto a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and proteins were transferred to 0.2-mm nitrocellulose membrane (Schleicher and Schuell, Keene, NH, USA) by electroblotting. Primary antibodies included anti-CD82 (mouse monoclonal IgG; Invitrogen), anti-IL-8 (mouse monoclonal IgG; R&D Systems, Minneapolis, MN, USA), anti-b-actin IgG1 (Cell Signaling Technologies, Danvers, MA, USA) and anti-p21 (human polyclonal IgG; Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Secondary antibodies were peroxidase-conjugated goat anti-mouse IgG and goat anti-rabbit IgG. Proteins were detected using the Enhanced Chemiluminescence Detection System (Amersham Pharmacia Biotech, Arlington Heights, IL, USA). Nitrocellulose membranes were subsequently stripped and reprobed using anti-b-actin as described above.
Enzyme-linked immunosorbent assay. Cell-free media from 3.1-or CD82-expressing A375M, and UACC cultures were collected after 24 h. The medium was spun at 430 g and supernatants were extracted from cell debris. Supernatants were stored at À 20 1C until use. Sandwich ELISA for individual cytokines was performed at the Pennsylvania State University General Clinical Research Center using standard protocols. Briefly, each 48-well plate was coated with the appropriate mouse anti-human capture antibody diluted in 0.1 M NaHCO 3 (pH 8.2) at a final concentration of 2 mg/ml (R&D Systems). Plates were incubated overnight at 4 1C. Next day, each plate was blocked for 2 h at room temperature using PBS with 1% bovine serum albumin. Samples and standards were added at 100 ml per well and incubated overnight at 4 1C (R&D Systems). Finally, wells were incubated for 2 h at room temperature in detection antibody (concentration: 5 mg/ml) (R&D Systems). Plates were read on a Packard spectacount plate reader at a wavelength of 405-415 nm.
Adhesion assay. HUVECs were seeded into 24-well plates and grown to confluency. We trypsinized A375M and UACC 903M melanoma cells and resuspended them in DMEM with 10% FBS. Following recovery, 10 3 melanoma cells were incubated with the confluent bottom cell layers in the presence or absence of antibody against CD82 or DARC antibody. After 15 min or 1 h, wells were washed with DMEM three times and then the cells were incubated for 12 h at 37 1C. The number of GFP-labeled melanoma cells attached to the confluent HUVEC monolayers were counted using a NIKON fluorescence microscope and the percentage of attached cells was calculated. For each well, we counted eight fields and averaged the number of cells in each well.
Statistical analysis. Statistical significance for multiple comparisons between groups was conducted using analysis of variance, followed by appropriate post hoc tests. For comparisons between two samples, t-tests were used. Results were considered significant at a P-value of o0.05. Inhibition of IL-8-mediated endothelial gap formation by CD82/KAI P Khanna et al
